Nanoscan Imaging, LLC
NanoScan’s platform technologies promise to change in the way MDs view cancer, cardiovascular disease, autoimmune and neurogenic disorders
NanoScan Imaging (“NSI”) was formed to continue the development of N1177, a reimbursable CT contrast agent that will change the way MDs view cancer and CVD.. Our management team and BOD have rich backgrounds in the technology. N1177’s clinically experienced platform targets the $5.3 B radiopharmaceutical market, has an open IND and IP protection through 2028. NSI is talking to acquisition candidates and plans to sell N1177 in 2-3 years.